Arcutis Biotherapeutics Reports Q3 Net Product Revenues of $143.9 Million and Provides 2026 Guidance
Arcutis Biotherapeutics (ARQT) reported third-quarter net product revenues of $143.9 million, driven by strong demand for its ZORYVE product line. CEO Todd Watanabe noted that the company is strategically reinvesting cash flows generated from ZORYVE to support ongoing growth and development. Looking ahead, Arcutis has provided 2026 net revenue guidance in the range of $535 million to $545 million. The company is also preparing for a significant regulatory milestone with an upcoming PDUFA date on February 23, 2027, regarding its infant atopic dermatitis (AD) treatment.
Tickers: $ARQT